非小细胞肺癌18F-FDG PET/CT显像标准化摄取值与肿瘤分子标志物表达的相关性

目的 分析非小细胞肺癌18F-FDG 标准化摄取值(SUV)与GLUT1、Ki-67、MVD、survivin及cyclinA表达的相关性.方法 收集经18F-FDG PET/CT检查且手术切除的非小细胞肺癌33例,采用SP免疫组织化学方法分别检测GLUT1、Ki-67、MVD、survivin及cyclinA,探讨其与SUV的相关性及GLUT1与Ki-67、MVD、survivin及cyclinA 的相关性;分别将病灶按大小(以瘤体3 cm为界)、有无纵隔及肺门淋巴结转移、肺癌的组织学类型分为两组,分别比较两组病灶的GLUT1、Ki-67、MVD、survivin及cyclinA的表达差异是否有统计学意义.结果 33例NSCLC 标本中GLUT1阳性率为66.67%;Ki-67阳性率为72.73%;CD34阳性率为100%.标本平均微血管计数为(12.6±2.9)条,实际范围为12～56条;survivin阳性率为84.85%; cyclinA阳性率为27.27%.结论 FDG SUV与GLUT1呈线性回归关系,与MVD、Ki-67、survivin及cyclinA无相关性. GLUT1、Ki-67、MVD、survivin及cyclinA的表达与病灶大小及有无淋巴结转移无相关性;GLUT1和Ki-67的表达与肺癌的组织学类型有相关性,MVD、survivin及cyclinA的表达与肺癌的组织学类型无相关性.

Correlation between 18F-FDG PET/CT SUV and immunohistochemical expression of tumor associated molecular markers in non-small-cell lung cancer

Objective To analyze the correlation between 18F-FDG SUV and immunohistochemical index including GLUT1, Ki-67, MVD, survivin and cyclinA in non-snall-cell lung cancer. Methods Thirty-three patients with NSCLC underwent preoperative PET/CT examination and surgical operation. All patients were divided into two groups according to the size of tumor (cutoff=3 cm), metastasis of mediastinal or hilar lymph nodes or not, and histological types of the cancer, respectively. The expression of GLUT1, Ki-67, MVD, survivin and cyclinA were estimated with SP immunohistochemical technique, and were analyzed statistically to reveal the correlation to FDG SUV. Results The rate of positive expression of GLUT1, Ki-67 and CD34 were 66.67%, 72.73% and 100%, respectively. The mean value of CD34 in all 33 patients was 12.6±2.9 (12-56). The rate of positive expression of survivin was 84.85%, and the corresponding data of cyclinA was 27.27%. Conclusion There is linear correlation between FDG PET SUV and GLUT1, but not between FDG PET SUV and Ki-67, MVD, survivin and cyclinA. The expressions of GLUT1, Ki-67, MVD, survivin and cyclinA are not related with the size of tumor, nor metastasis of lymph nodes. The expression of GLUT1 and Ki-67 is related with histological types of the cancer, but not with MVD, survivin and cyclinA.